Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC

To explore the efficacy and safety of Tislelizumab combined with chemotherapy and relayed radiotherapy in the first-line treatment of extensive small cell lung cancer

Trial Details

NCT ID
NCT06838208
Phase
PHASE2
Sponsor
Anhui Provincial Cancer Hospital
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Tislelizumab, Carboplatin /Cisplatin, Etoposide
Locations (sample)
  • Hefei, Anhui, China|31.86389,117.28083

Key Eligibility Criteria

  • Age≥18 years old, male or female, signed Informed Consent Form (ICF);
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
  • Histologically or cytologically confirmed ES-SCLC;
  • No prior systemic treatment for ES-SCLC;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →